Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

Ulrike Heider, MD, Martin Kaiser, MD, Ivana Zavrski, MD, Jan Sterz, MD, Christian Jakob, MD, Claudia Fleissner, MD, Monica Hecht, MD, Lorenz Kleeberg, MD, Christian Braun, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2006) 108 (11): 2509.

https://doi.org/10.1182/blood.V108.11.2509.2509

Published: 2006

Journal Articles

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Jan Sterz, MD, Christian Jakob, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Martin Kaiser, MD, Claudia Fleissner, MD, Lorenz Kleeberg, MD, Ulrike Heider, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD, Ivana Zavrski, MD

Blood (2006) 108 (11): 3475.

https://doi.org/10.1182/blood.V108.11.3475.3475

Published: 2006

Journal Articles

Bortezomib Inhibits Human Osteoclastogenesis.

Ivana Zavrski, MD, Monica Hecht, PhD, Holger Krebbel, Claudia Fleissner, MD, Maren Mieth, PhD, Martin Kaiser, MD, Ulrike Heider, MD, Christian Jakob, MD, Jan Sterz, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2006) 108 (11): 1395.

https://doi.org/10.1182/blood.V108.11.1395.1395

Published: 2006

Journal Articles

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Christian Jakob, Karl Egerer, Peter Liebisch, Seval Türkmen, Ivana Zavrski, Ulrike Kuckelkorn, Ulrike Heider, Martin Kaiser, Claudia Fleissner, Jan Sterz, Lorenz Kleeberg, Eugen Feist, Gerd-R. Burmester, Peter-M. Kloetzel, Orhan Sezer

Blood (2006) 109 (5): 2100–2105.

https://doi.org/10.1182/blood-2006-04-016360

Published: 2006

Journal Articles

Treatment of Bortezomib Increases Osteoblast Function in Patients with Multiple Myeloma.

Ulrike Heider, MD, Martin Kaiser, MD, Christian Müller, MD, Carsten-Oliver Schulz, MD, Christian Jakob, MD, Ivana Zavrski, MD, Jan Eucker, MD, Jan Sterz, MD, Lorenz Kleeberg, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 3457.

https://doi.org/10.1182/blood.V106.11.3457.3457

Published: 2005

Journal Articles

Valproic Acid Inihibts Histone Deacetylases and Proliferation and Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma.

Martin Kaiser, MD, Ulrike Heider, MD, Ivana Zavrski, MD, Jan Sterz, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 5165.

https://doi.org/10.1182/blood.V106.11.5165.5165

Published: 2005

Journal Articles

Bortezomib (PS-341) Sensitizes Multiple Myeloma Cell Lines to Etoposide-Induced Apoptosis.

Ivana Zavrski, MD, Martin Kaiser, MD, Marleen Rosche, MD, Ulrike Heider, MD, Christian Jakob, MD, Claudia Fleissner, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 5166.

https://doi.org/10.1182/blood.V106.11.5166.5166

Published: 2005

Journal Articles

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production.

Ulrike Heider, MD, Martin Kaiser, MD, Ivana Zavrski, MD, Jan Sterz, MD, Christian Jakob, MD, Claudia Fleissner, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 4817.

https://doi.org/10.1182/blood.V106.11.4817.4817

Published: 2005

Journal Articles

Serum Total-RANKL Is Elevated in Patients with Multiple Myeloma, Increases with ISS Stage and Decreases after Induction Therapy.

Christian Jakob, MD, Jan Sterz, MD, Lorenz Kleeberg, MD, Ivana Zavrski, MD, Martin Kaiser, MD, Jan Eucker, MD, Ulrike Heider, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 2511.

https://doi.org/10.1182/blood.V106.11.2511.2511

Published: 2005

Journal Articles

Induction of Apoptosis in Multiple Myeloma by Ligands of Peroxisome Proliferator-Activated Receptor γ (PPAR-γ).

Jan Eucker, MD, Katharina Baengeroth, Ivana Zavrski, MD, Holger Krebbel, Chuanbing Zang, PhD, Ulrike Heider, MD, Christian Jakob, MD, Elena Elstner, PhD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2004) 104 (11): 4848.

https://doi.org/10.1182/blood.V104.11.4848.4848

Published: 2004

Journal Articles

Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma.

Christian Jakob, MD, Karl Egerer, PhD, Eugen Feist, MD, Ivana Zavrski, MD, Jan Eucker, MD, Ulrike Heider, MD, Gerd Burmester, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD

Blood (2004) 104 (11): 1486.

https://doi.org/10.1182/blood.V104.11.1486.1486

Published: 2004

Journal Articles

RANK ligand and osteoprotegerin in myeloma bone disease

Orhan Sezer, Ulrike Heider, Ivana Zavrski, Christian Alexander Kühne, Lorenz Christian Hofbauer

Blood (2003) 101 (6): 2094–2098.

https://doi.org/10.1182/blood-2002-09-2684

Published: 2003

Journal Articles

Immunocytochemistry reveals RANKL expression of myeloma cells

Orhan Sezer, Ulrike Heider, Christian Jakob, Ivana Zavrski, Jan Eucker, Kurt Possinger, Christine Sers, Veit Krenn

Blood (2002) 99 (12): 4646–4647.

https://doi.org/10.1182/blood-2002-01-0148

Published: 2002

NARROW

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Bortezomib Inhibits Human Osteoclastogenesis.

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Treatment of Bortezomib Increases Osteoblast Function in Patients with Multiple Myeloma.

Valproic Acid Inihibts Histone Deacetylases and Proliferation and Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma.

Bortezomib (PS-341) Sensitizes Multiple Myeloma Cell Lines to Etoposide-Induced Apoptosis.

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production.

Serum Total-RANKL Is Elevated in Patients with Multiple Myeloma, Increases with ISS Stage and Decreases after Induction Therapy.

Induction of Apoptosis in Multiple Myeloma by Ligands of Peroxisome Proliferator-Activated Receptor γ (PPAR-γ).

Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma.

RANK ligand and osteoprotegerin in myeloma bone disease

Immunocytochemistry reveals RANKL expression of myeloma cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only